Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Free Cash Flow (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Free Cash Flow readings, the most recent being -$6.0 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 304.48% to -$6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.5 million, a 149.42% decrease, with the full-year FY2025 number at -$12.5 million, down 146.23% from a year prior.
  • Free Cash Flow hit -$6.0 million in Q4 2025 for Fennec Pharmaceuticals, down from $1.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $37.3 million in Q1 2024 to a low of -$8.4 million in Q2 2024.
  • Median Free Cash Flow over the past 5 years was -$3.6 million (2021), compared with a mean of -$1.6 million.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 768.94% in 2024 and later tumbled 304.48% in 2025.
  • Fennec Pharmaceuticals' Free Cash Flow stood at -$3.0 million in 2021, then tumbled by 129.95% to -$6.8 million in 2022, then increased by 28.55% to -$4.9 million in 2023, then skyrocketed by 69.67% to -$1.5 million in 2024, then tumbled by 304.48% to -$6.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$6.0 million (Q4 2025), $1.5 million (Q3 2025), and -$3.7 million (Q2 2025) per Business Quant data.